Supercharge Your Innovation With Domain-Expert AI Agents!

Novel molecules for therapy and diagnosis

A technology for binding molecules, synuclein, applied in the field of α-synuclein antibody or its antigen-binding fragment or its derivatives

Pending Publication Date: 2022-03-18
AC IMMUNE SA
View PDF21 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To our knowledge, there are currently no approved or clinically available biomarkers for monitoring pathological α-synuclein levels on the market, despite a critical need for Parkinson's disease research and drug development ( Eberling et al., JParkinsons Dis. 2013;3(4):565-7)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel molecules for therapy and diagnosis
  • Novel molecules for therapy and diagnosis
  • Novel molecules for therapy and diagnosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0930] Preparation of α-synuclein liposome vaccine composition

[0931] Liposome-based antigenic constructs were prepared according to the protocol disclosed in WO2012 / 055933. Liposomal vaccine with human full-length α-synuclein as antigen for antibody production (Table 2, SEQ ID NO: 1) or liposomal vaccine with α-synuclein peptide as antigen for antibody production .

[0932] Table 2: Antigen description

[0933]

[0934] mouse immunization

[0935] Female C57BL / 6JOlaHsd and BALB / cOlaHsd mice (Envigo, USA) were vaccinated at 10 weeks of age. The C57BL / 6JOlaHsd substrain is known to have a spontaneous deletion of the α-synuclein gene. Mice were vaccinated with a vaccine in which synthetic monophosphorylhexayl lipid A 3-deacylated (3D-(6-acyl) ) (Avanti Polar Lipids, USA) containing α-synuclein peptide or human full-length α-synuclein present on the surface of liposomes.

[0936] Mice were vaccinated by subcutaneous injection (s.c.) on days 0, 5, 8, 21, 35, 84 and in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to novel molecules useful in the prevention, amelioration, treatment and / or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, a-synuclein, A-syn, alpha-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and / or Lewy neurons, such as, but not limited to, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein and Alpha-synuclein. For example, Parkinson's disease, multi-system atrophy, dementia with Lewy bodies (LBD; dementia with Lewy bodies (DLB) ('pure 'dementia with Lewy bodies), dementia with Parkinson's disease (PDD) or diffuse Lewy body disease. The present invention relates to alpha-synuclein binding molecules, in particular alpha-synuclein antibodies or antigen binding fragments or derivatives thereof, and uses thereof. The molecules of the invention may also be used to determine the predisposition of predisposition to such a condition, disease, or abnormality, to monitor a residual condition, disease, or abnormality, or to predict the responsiveness of a patient suffering from such a condition, disease, or abnormality to a treatment with a certain drug.

Description

technical field [0001] The present invention relates to can be used for preventing, alleviating, treating and / or diagnosing and alpha-synuclein (alpha-synuclein, A-synuclein, alpha synuclein, A-syn, alpha-syn, aSyn, a-syn) aggregate-associated diseases, disorders, and abnormalities including, but not limited to, Lewy bodies and / or Lewy neurites, such as Parkinson's disease, multiple Systemic atrophy, Lewy Body dementia (LBD; dementia with Lewy body (DLB) ("pure" dementia with Lewy bodies), Parkinson's disease dementia (PDD)), or diffuse Lewy Physical illness. The present invention relates to α-synuclein binding molecules, especially α-synuclein antibodies or antigen-binding fragments or derivatives thereof and uses thereof. The molecules of the invention can also be used to determine a predisposition to such a condition, disease or disorder, to monitor a residual condition, disease or disorder, or to predict the response to a drug in a patient suffering from such a condition...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P25/28C07K16/18
CPCC07K2317/24C07K16/18C07K2317/34C07K2317/76A61P25/28C07K2317/92G01N33/6896G01N33/582A61K2039/505A61P25/00
Inventor 尔必达·齐卡约翰·瓦尔纳罗曼·克里斯蒂安·奥利耶扬·彼得·亨宁·斯特尔
Owner AC IMMUNE SA
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com